NewsMeter
Philadelphia-based Berger Montague PC filed a securities fraud class action against ADMA Biologics, Inc. (NASDAQ: ADMA) on July 16, 2026.
The suit covers investors who purchased or acquired ADMA common stock during a stated class period. Berger Montague, a national plaintiffs' firm, is soliciting inquiries from eligible shareholders.
Scope of the complaint The complaint names ADMA Biologics as defendant. The covered investor class consists of those who purchased or acquired ADMA common stock during the specified window.
Berger Montague's announcement did not detail the specific allegations, claimed damages, or the precise class period dates.
Keep reading